2015 Doctors Pharmacology 
pharmaphorum
DECEMBER 15, 2022
Ofev (nintedanib) has been recommended since 2015 for NHS use in IPF patients who have a forced vital capacity (FVC) value of 50% to 80% of normal, but will now be an option for people with less severe disease, i.e. an FVC of more than 80%. The post NICE backs use of Boehringer’s Ofev in IPF from diagnosis appeared first on.
European Pharmaceutical Review
MARCH 11, 2024
In fact, a study published in 2023 in The Lancet HIV revealed that women and men with HIV at age 40 had an average of 39 and 37 years of life left, respectively – only a few years less than that of the general population – if they started antiretroviral therapy (ART) after 2015. World Health Organization. The Global Health Observatory.
Expert insights. Personalized for you.
105 
Let's personalize your content